of approximately 8-10 months and a median overall survival that falls below two years in both squamous and nonsquamous histologies [2][3][4][5][6]. Immune checkpoint inhibitors (ICIs) administered as monotherapy in selected patients with high programmed-death ligand 1 (PD-L1) expression achieve better outcomes that, nevertheless, confer long-term responses only in a minority of patients [7][8][9].Patients with advanced NSCLC who progress after chemoimmunotherapy, given either concurrently or sequentially, currently have limited treatment options. Second-line chemotherapy with docetaxel, administered alone or in combination with anti-angiogenic agents (ramucirumab, nindetanib), offers modest clinical outcomes [10,11]. ICIs given as monotherapy have been proven superior to docetaxel in patients progressing after first-line chemotherapy [12][13][14][15]. Recent advances in elucidating the molecular biology of the disease have led to the identification of molecular pathways that could be exploited therapeutically in an effort to improve outcomes by overcoming resistance to immunotherapy and chemotherapy [1]. The patterns of resistance to immunotherapy have been extensively studied and may involve primary or secondary resistance as well as intrinsic and extrinsic mechanisms encompassing diverse molecular pathways [16].Consequently, potential strategies to overcome acquired resistance may include, among others:-Combinations of immune checkpoint-modifying agents that either inhibit suppression of immune cells (antagonists) or activate the immune system (agonists). Examples include the synergistic activity of PD-(L) 1 inhibitors with anti-CTLA4 or anti-TIGIT monoclonal antibodies, as well as the combination with agonists of immune activation, such as OX-40 monoclonal antibodies [17] -Combinations of ICIs with molecular targeted agents, such as tyrosine kinase inhibitors, that interfere with diverse molecular pathways, including cellular proliferation, apoptosis regulation, inflammation, DNA repair, epigenetic modification and angiogenesis. Metabolic pathways that are often associated with immune regulation involve the mitogen-activated protein kinase (MAPK), the phosphatidyl-inositol -3-kinase (PI3K) and the signaling transducer and activator of transcription (STAT) molecular pathways [18] -Biotechnological advances have enabled the clinical development of novel molecules with unique properties, such as antibody-drug conjugates and bi-specific antibodies, that may act as "engagers" of the immune system to cancer cells, triggering thus the anti-tumor activity of the immune system against neoantigens [19,20] -Finally, the role of the tumor microenvironment and the identification of potential biomarkers of activity/resistance to novel treatment strategies is currently a field of active investigation to enhance anti-tumor immunity by studying the interaction of the tumor cells with the stroma and the surrounding host niche [21] In the current issue of Frontiers, we present eight (8) high-quality articles that evaluate the Discovering ways and strategies to overcome resistance to immunotherapy, chemotherapy and targeted agents is a constantly evolving research field. In this ever-lasting scientific endeavor, the only road to successful outcomes passes through sound scientific ratiional, robust pre-clinical experimentation and well-designed and executed clinical trials. The algorithmic use of potent biomarkers, including liquid biopsies, will likely assist in identifying the subgroups of patients who will benefit the most from each experimental strategy. The collective goal of these strategies will be to implement individualized treatment approaches after chemotherapy and immunotherapy failure, based on the unique biological characteristics and mechanisms of primary or acquired resistance for each one of our patients. This personalized approach paves the way for precision oncology, which is the optimal strategy to improve the lives of our patients.
11 Authors
- FB
Fenglong Bie
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- HT
He Tian
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- NS
Nan Sun
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- RZ
Ruochuan Zang
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- MZ
Moyan Zhang
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- PS
Peng Song
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- LL
Lei Liu
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- YP
Yue Peng
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- GB
Guangyu Bai
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- BZ
Bolun Zhou
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- SG
Shugeng Gao
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
10 Authors
- CK
Chul Kim
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- SV
Stephen V. Liu
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- JC
Jennifer Crawford
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- TT
Tisdrey Torres
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- VC
Vincent Chen
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- JT
Jillian Thompson
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- MT
Ming Tan
Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University, United States
- GE
Giuseppe Esposito
Department of Radiology, Georgetown University Hospital, United States
- DS
Deepa S. Subramaniam
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States
- GG
Giuseppe Giaccone
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, United States


